Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CAMTA1

Gene summary for CAMTA1

Gene summary.

Gene information	Species	Human
	Gene symbol	CAMTA1
	Gene ID	23261
	Gene name	calmodulin binding transcription activator 1
	Gene Alias	CANPMR
	Cytomap	1p36.31-p36.23
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	Q9Y6Y1

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23261	CAMTA1	P28T-E	Human	Esophagus	ESCC	2.38e-32	8.22e-01	0.1149
23261	CAMTA1	P30T-E	Human	Esophagus	ESCC	6.83e-31	1.18e+00	0.137
23261	CAMTA1	P31T-E	Human	Esophagus	ESCC	8.01e-67	1.27e+00	0.1251
23261	CAMTA1	P32T-E	Human	Esophagus	ESCC	1.76e-52	1.25e+00	0.1666
23261	CAMTA1	P36T-E	Human	Esophagus	ESCC	7.05e-16	7.45e-01	0.1187
23261	CAMTA1	P37T-E	Human	Esophagus	ESCC	8.14e-41	1.25e+00	0.1371
23261	CAMTA1	P38T-E	Human	Esophagus	ESCC	2.90e-08	6.35e-01	0.127
23261	CAMTA1	P39T-E	Human	Esophagus	ESCC	1.11e-12	2.46e-01	0.0894
23261	CAMTA1	P40T-E	Human	Esophagus	ESCC	2.94e-20	1.03e+00	0.109
23261	CAMTA1	P42T-E	Human	Esophagus	ESCC	3.52e-17	7.28e-01	0.1175
23261	CAMTA1	P44T-E	Human	Esophagus	ESCC	1.05e-14	4.60e-01	0.1096
23261	CAMTA1	P47T-E	Human	Esophagus	ESCC	6.16e-20	4.27e-01	0.1067
23261	CAMTA1	P48T-E	Human	Esophagus	ESCC	2.73e-19	5.18e-01	0.0959
23261	CAMTA1	P49T-E	Human	Esophagus	ESCC	6.66e-20	2.16e+00	0.1768
23261	CAMTA1	P52T-E	Human	Esophagus	ESCC	8.69e-42	1.21e+00	0.1555
23261	CAMTA1	P54T-E	Human	Esophagus	ESCC	8.27e-39	1.30e+00	0.0975
23261	CAMTA1	P56T-E	Human	Esophagus	ESCC	3.65e-11	1.75e+00	0.1613
23261	CAMTA1	P57T-E	Human	Esophagus	ESCC	3.72e-26	7.34e-01	0.0926
23261	CAMTA1	P61T-E	Human	Esophagus	ESCC	1.14e-07	5.18e-01	0.099
23261	CAMTA1	P62T-E	Human	Esophagus	ESCC	2.22e-60	1.23e+00	0.1302

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00353049	Breast	Precancer	regulation of protein dephosphorylation	14/1080	90/18723	6.16e-04	7.72e-03	14
GO:003530414	Breast	IDC	regulation of protein dephosphorylation	18/1434	90/18723	1.39e-04	2.48e-03	18
GO:003530423	Breast	DCIS	regulation of protein dephosphorylation	18/1390	90/18723	9.33e-05	1.71e-03	18
GO:00353039	Breast	DCIS	regulation of dephosphorylation	18/1390	128/18723	6.44e-03	4.58e-02	18
GO:00508481	Breast	DCIS	regulation of calcium-mediated signaling	12/1390	73/18723	7.17e-03	4.85e-02	12
GO:0016311	Colorectum	AD	dephosphorylation	123/3918	417/18723	1.84e-05	3.82e-04	123
GO:0006470	Colorectum	AD	protein dephosphorylation	88/3918	281/18723	2.56e-05	4.89e-04	88
GO:0035303	Colorectum	AD	regulation of dephosphorylation	46/3918	128/18723	6.20e-05	1.04e-03	46
GO:0035304	Colorectum	AD	regulation of protein dephosphorylation	33/3918	90/18723	4.23e-04	4.77e-03	33
GO:0035306	Colorectum	AD	positive regulation of dephosphorylation	22/3918	59/18723	2.86e-03	2.14e-02	22
GO:00353032	Colorectum	MSS	regulation of dephosphorylation	41/3467	128/18723	1.64e-04	2.33e-03	41
GO:00353042	Colorectum	MSS	regulation of protein dephosphorylation	30/3467	90/18723	5.58e-04	6.19e-03	30
GO:00064702	Colorectum	MSS	protein dephosphorylation	73/3467	281/18723	1.15e-03	1.12e-02	73
GO:00163112	Colorectum	MSS	dephosphorylation	101/3467	417/18723	1.98e-03	1.70e-02	101
GO:00163113	Colorectum	FAP	dephosphorylation	95/2622	417/18723	7.07e-07	3.32e-05	95
GO:00064704	Colorectum	FAP	protein dephosphorylation	69/2622	281/18723	1.47e-06	6.39e-05	69
GO:00353034	Colorectum	FAP	regulation of dephosphorylation	36/2622	128/18723	2.22e-05	5.28e-04	36
GO:00353044	Colorectum	FAP	regulation of protein dephosphorylation	24/2622	90/18723	1.12e-03	1.08e-02	24
GO:0048016	Colorectum	FAP	inositol phosphate-mediated signaling	16/2622	55/18723	2.78e-03	2.15e-02	16
GO:00353061	Colorectum	FAP	positive regulation of dephosphorylation	16/2622	59/18723	5.95e-03	3.75e-02	16

Page: 1 2 3 4 5 6

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CAMTA1

SNV

Missense_Mutation

c.4546N>G

p.Leu1516Val

p.L1516V

Q9Y6Y1

protein_coding

deleterious(0)

probably_damaging(0.984)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

CAMTA1

SNV

Missense_Mutation

c.2635N>C

p.Glu879Gln

p.E879Q

Q9Y6Y1

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-A8-A0A7-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

CAMTA1

SNV

Missense_Mutation

novel

c.148A>C

p.Lys50Gln

p.K50Q

Q9Y6Y1

protein_coding

deleterious(0)

probably_damaging(0.915)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CAMTA1

SNV

Missense_Mutation

novel

c.1369N>T

p.Pro457Ser

p.P457S

Q9Y6Y1

protein_coding

tolerated_low_confidence(0.35)

benign(0.003)

TCGA-B6-A3ZX-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

CAMTA1

SNV

Missense_Mutation

c.860C>G

p.Ser287Trp

p.S287W

Q9Y6Y1

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-BH-A0HK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

CAMTA1

SNV

Missense_Mutation

novel

c.4383C>G

p.Asn1461Lys

p.N1461K

Q9Y6Y1

protein_coding

tolerated(0.05)

benign(0.025)

TCGA-BH-A18V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

CAMTA1

SNV

Missense_Mutation

c.3028N>A

p.Gly1010Ser

p.G1010S

Q9Y6Y1

protein_coding

tolerated(0.4)

benign(0.014)

TCGA-C8-A12V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

CAMTA1

SNV

Missense_Mutation

c.403G>C

p.Glu135Gln

p.E135Q

Q9Y6Y1

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-C8-A26Y-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CAMTA1

SNV

Missense_Mutation

rs771378439

c.1246G>A

p.Ala416Thr

p.A416T

Q9Y6Y1

protein_coding

tolerated_low_confidence(0.13)

benign(0.001)

TCGA-LL-A7T0-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CAMTA1

insertion

Frame_Shift_Ins

novel

c.1291_1292insAGAAAAGAAAAACCATCAGAGTTATAAT

p.Leu431GlnfsTer17

p.L431Qfs*17

Q9Y6Y1

protein_coding

TCGA-A2-A0EQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1